Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Selective immunosuppression

L Adorini1, J C Guéry, G Rodriguez-Tarduchy

  • 1Roche Milano Ricerche, Italy.

Immunology Today
|June 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protective effect of UDCA against IL-11- induced cardiac fibrosis is mediated by TGR5 signalling.

Frontiers in cardiovascular medicine·2024
Same author

Farnesoid X receptor activation by the novel agonist TC-100 (3α, 7α, 11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid) preserves the intestinal barrier integrity and promotes intestinal microbial reshaping in a mouse model of obstructed bile acid flow.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2022
Same author

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.

PloS one·2019
Same author

Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model.

Journal of endocrinological investigation·2019
Same author

Therapeutic effects of obeticholic acid (OCA) treatment in a bleomycin-induced pulmonary fibrosis rat model.

Journal of endocrinological investigation·2018
Same author

Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.

Biochimica et biophysica acta. Molecular basis of disease·2017
Same journal

Foreword.

Immunology today·2020
Same journal

The origin and significance of anti-DNA antibodies.

Immunology today·2014
Same journal

Mutations of class II MHC molecules.

Immunology today·2014
Same journal

Antigen processing at the molecular level.

Immunology today·2014
Same journal

Phenotypically and functionally distinct T-cell subsets in anti-tumor responses.

Immunology today·2014
Same journal

Are MHC class II-restricted cytotoxic T lymphocytes important?

Immunology today·2014
See all related articles

Selective immunosuppression strategies targeting antigen-presenting cells, autoreactive T cells, and regulatory T cells show promise for preventing and treating autoimmune diseases in experimental models.

Area of Science:

  • Immunology
  • Autoimmune Diseases
  • Immunosuppression

Background:

  • Experimental models of autoimmune diseases provide insights into disease pathogenesis.
  • Key cellular players in autoimmune diseases include antigen-presenting cells, autoreactive T cells, and regulatory T cells.

Purpose of the Study:

  • To discuss selective immunosuppression approaches for autoimmune diseases.
  • To examine the potential applicability of these strategies to human autoimmune disease treatment.

Main Methods:

  • Review of experimental models of autoimmune diseases.
  • Analysis of selective interference with specific immune cell activation.

Main Results:

  • Selective interference with antigen-presenting cells, autoreactive T cells, or regulatory T cells can prevent or treat autoimmune diseases in experimental settings.

Related Experiment Videos

  • These targeted approaches offer potential for selective immunosuppression.

    • Conclusions:

    • Strategies for selective immunosuppression are effective in experimental autoimmune disease models.
    • Further research may translate these findings into novel treatments for human autoimmune diseases.